Rohini Sharma is a Reader in Clinical Pharmacology and Medical Oncology. She is also a Consultant Medical Oncologist based at the Hammersmith Hospital campus of Imperial College Healthcare NHS Trust. Her clinical and research interests are in Hepatocellular cancer (HCC), Neuroendocrine tumours (NETs) and development of novel biomarkers. To this end, Rohini is the Oncology lead for the specialist Hepato-Oncology Clinic, a unique service where patients are jointly managed by a Hepatologist and Medical Oncologist with a view to improving clinical outcomes and promoting research (http://www.imperial.nhs.uk/services/liver/livercancer/). Rohini is the lead of the liver cancer research group at Imperial http://www.imperial.ac.uk/department-surgery-cancer/research/cancer/groups/liver-cancer/. She is also the Oncology lead for the management of NETs within the Trust.
Rohini Sharma completed her medical training at the University of Adelaide, Australia and undertook her specialist oncology training at the Royal Prince Alfred Hospital, Sydney and her clinical pharmacology training at Westmead Hospital, Sydney. Rohini was awarded an NHMRC Fellowship to complete her PhD at the Westmead Millennium Institute, University of Sydney, Australia. She was awarded the prestigious Higher Education Funding Council for England Clinical Senior Lecturer position in May 2010.
Her current research interests include early phase clinical trials, drug development and PET imaging within the Comprehensive Cancer Imaging Center. Her group is also involved in the discovery and validation of novel targeted therapies for the management of HCC and NET. She is author of over 80 publications in these areas.
et al., 2012, Imaging of cellular proliferation in liver metastasis by [<SUP>18</SUP>F]fluorothymidine positron emission tomography: effect of therapy, Physics in Medicine and Biology, Vol:57, ISSN:0031-9155, Pages:3419-3433